What is Rhythm Pharmaceuticals, Inc.'s Shariah compliance score?

Rhythm Pharmaceuticals, Inc.'s (RYTM) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Rhythm Pharmaceuticals, Inc. pass AAOIFI screening?

Rhythm Pharmaceuticals, Inc. (RYTM) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (RYTM: 1.4%), (3) interest-bearing deposits below 30% (RYTM: 5.3%), and (4) prohibited income below 5% (RYTM: 11.7%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Rhythm Pharmaceuticals, Inc. stock?

Rhythm Pharmaceuticals, Inc. (RYTM) has a non-permissible income ratio of 11.69%. Muslim investors should purify this percentage of any dividends received and capital gains realized from RYTM shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Rhythm Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Rhythm Pharmaceuticals, Inc. (RYTM) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about RYTM's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

RYTM: Is Rhythm Pharmaceuticals, Inc. Halal?

Rhythm Pharmaceuticals, Inc.

NASDAQHealthcareUS

$115.48

+0.92%

Market Cap: 7.9B

Compliance Status

Not Halal

Screened on Jul 17, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Rhythm Pharmaceuticals, Inc. (RYTM) halal? Not Halal. Based on AAOIFI screening, Rhythm Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

1.4% of 30.0% limit

What this means for you

Most scholars advise not holding RYTM

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 17, 2026

Compliance History

Not Halal, unchanged since Jun 2026.

No status changes recorded since we began tracking.

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.45

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

+0.01%

0075.KLA+

LYC Healthcare Bhd

$0.01

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.47

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.29

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track RYTM and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. (RYTM) halal to invest in?

Rhythm Pharmaceuticals, Inc. (RYTM) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Rhythm Pharmaceuticals, Inc. get a F compliance rating?

Rhythm Pharmaceuticals, Inc. (RYTM) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.4% (limit 30%); interest-bearing deposits of 5.3% (limit 30%); prohibited income of 11.69% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Rhythm Pharmaceuticals, Inc.'s Shariah verdict?

Rhythm Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Rhythm Pharmaceuticals, Inc. re-screened for Shariah compliance?

Rhythm Pharmaceuticals, Inc. (RYTM) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 17, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.